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We have shown that folate-induced kidney dysfunction and
interstitial fibrosis predisposes mice to sepsis mortality.
Agents that increase survival in normal septic mice were
ineffective in a two-stage kidney disease model. Here we used
the 5/6 nephrectomy mouse model of progressive chronic
kidney disease (CKD) to study how CKD affects acute kidney
injury (AKI) induced by sepsis. We induced sepsis using cecal
ligation and puncture and found that the presence of CKD
intensified the severity of kidney and liver injury, cytokine
release, and splenic apoptosis. Accumulation of High Mobility
Group Box Protein-1 (HMGB1; a late proinflammatory
cytokine released from apoptotic cells), vascular endothelial
growth factor (VEGF), tumor necrosis factor (TNF)-a,
interleukin (IL)-6, or IL-10 was increased in CKD or sepsis
alone and to a greater extent in CKD-sepsis. Only part of the
increase was explained by decreased renal clearance.
Surprisingly, we found splenic apoptosis in CKD, even in the
absence of sepsis. Although VEGF neutralization with soluble
fms-like tyrosine kinase 1 (sFLT-1) (a soluble VEGF receptor)
effectively treated sepsis, it was ineffective against
CKD–sepsis. A single dose of HMGB1-neutralizing antiserum
administered 6h after sepsis alone was ineffective; however,
CKD–sepsis was attenuated by anti-HMGB1. Splenectomy
transiently decreased circulating HMGB1 levels, reversing the
effectiveness of anti-HMGB1 treatment on CKD–sepsis. Thus,
progressive CKD increases the severity of sepsis, in part,
by reducing the renal clearance of several cytokines.
CKD-induced splenic apoptosis and HMGB1 release could be
important common mediators for both CKD and sepsis.
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The rate of mortality from sepsis in critically ill patients is
increasing despite improvements in supportive care.1 The
translation of sepsis treatments from animal models into
humans has largely failed, partly because the less complex
animal models do not mimic human sepsis.2–6 Most patients
with sepsis have at least one underlying preexisting
(‘comorbid’) chronic illness.1,7,8 Those with chronic kidney
disease (CKD) have a higher prevalence, severity, and
mortality of sepsis.9,10 This might be caused by uremia-
induced leukocyte dysfunction (lymphocyte, monocyte,
neutrophil, and dendritic cell),11–16 inflammatory cytokine
accumulation from less renal clearance,17–20 or other co-
existing illness and so on.9 CKD is an important prognostic
risk factor in patients with sepsis.21,22 Recently, we showed
that folate-induced tubulointerstitial kidney fibrosis increases
the severity of all sepsis outcomes in a mouse cecal ligation
and puncture (CLP) model.23 However, the folate renal
fibrosis model lacks the renal progression, which is an
essential feature of human CKD.24 We recently developed a
modified surgical approach to inducing CKD in mice,25
where 5/6 nephrectomy (Nx) was performed in two stages:
resecting the upper and lower left kidney poles and using
Avitene hemostasis, followed by right nephrectomy 1 week
later, which mimics many aspects of the progressive natural
history of CKD patients. We found that two mouse strains,
CD-1 and 129S3, developed CKD, but another strain, C57BL/
6, did not develop CKD. In contrast, the severity of fibrotic
injury in the folate model was strain independent.25
In the current study, we reexamine the effect of preexisting
CKD on the severity of sepsis, using our progressive, 5/6 Nx
model. We previously reported initial studies that preexisting
5/6 Nx in CD-1 worsened subsequent sublethal CLP sepsis.23
We hypothesize that acute-on-CKD is a distinct entity that is
more than the sum of CKD and sepsis–acute kidney injury
(AKI). Therefore, we compare CKD (5/6 Nx), sepsis–AKI
(CLP), and acute-on-CKD (5/6 Nx-CLP) to determine which
sepsis-induced outcomes, including AKI, are exacerbated,
and determine whether ongoing inflammation and/or de-
creased clearance of proinflammatory cytokines can account
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for amplified/accelerated disease progression. We focus on
two cytokines that are implicated in both CKD and sepsis:
High Mobility Group Box Protein-1 (HMGB1), a late
proinflammatory cytokine released from apoptotic cells,26–29
and vascular endothelial growth factor (VEGF), an angiogen-
esis factor that promotes vascular leakage.23,30–32
RESULTS
Increased severity of sepsis after 5/6 Nx
We performed CLP at a time of advanced CKD: 4 weeks after
5/6 Nx in CD-1 mice (Supplementary Figure S1 online).25
CKD mice had more severe sepsis at 18 h after CLP compared
with mice subjected to CLP alone, as measured by kidney
injury (blood urea nitrogen (BUN) and renal tubular
vacuolization), liver injury (alanine transaminase (ALT),
aspartate transaminase (AST)), serum inflammatory cytokine
levels (tumor necrosis factor (TNF)-a, interleukin (IL)-6,
IL-10), and spleen apoptosis (Figures 1–3). Although there
was a similar trend for serum creatinine (Scr; Figure 1a), it
was not statistically significant; however, interpretation of Scr
levels is not straightforward because of sepsis-induced
reduction in creatinine production.8 Although the set of
organ-specific and systemic manifestations of sepsis that we
measured was quite diverse, 5/6 Nx increased the entire
set almost uniformly.
Increases in spleen apoptosis, serum HMGB1, and VEGF
after 5/6 Nx
Spleen apoptosis is a well-documented characteristic of
sepsis, associated with immune depression, which is
associated with increased mortality in mouse models and
also in humans.33 Compared with CLP alone, spleen
apoptosis in 5/6 Nx-CLP was substantially greater; however,
there was a significant increase in spleen apoptosis after 5/6
Nx alone (Figures 1 and 3). Because there were no reports in
the literature of CKD-associated spleen apoptosis, we
measured spleen apoptosis (by activated caspase 3 staining)
at different times during the course of CKD. To confirm this
finding, we took advantage of the strain-dependent suscep-
tibility toward developing CKD after 5/6 Nx, where C57BL/6
mice were not susceptible, but 129S3 and CD-1 developed
maximal CKD at 12 and 4 weeks, respectively.25 The amount
of spleen apoptosis (without sepsis) increased in CD-1 mice
and progressively increased in 129S3 mice (Figure 3e). Spleen
apoptosis was greater in 129S3 and CD-1 mice, compared
with C57BL/6 mice, and appeared to rise more rapidly in
CD-1 mice than in 129S3 mice (Figure 3e), corresponding to
the strain-dependent onset/severity of CKD.26 Spleen apo-
ptosis in the composite 2/6 Nx control group was not higher
than that in normal mice (not shown), indicating that the
healing process from the resected kidney wounds was not
enough to trigger spleen apoptosis. Because VEGF and
HMGB1 increase in human CKD,26,34,35 and splenic apo-
ptosis is associated with systemic accumulation of
HMGB1,27,36 we measured both VEGF and HMGB1. Serum
HMGB1 and VEGF levels increased after 5/6 Nx (Figure 4a
and b), which corresponded to progressive albuminuria seen
previously25 (Supplementary Figure S2 online). VEGF
appeared to increase more rapidly than HMGB1 (as early
as 1 week) after 5/6 Nx (Figure 4a and b), consistent with a
faster response of VEGF to injury. Other inflammatory
cytokines (TNF-a, IL-6, IL-10) were not elevated until 4
weeks (Figure 4c–e, data not shown).
Influence of kidney injury or removal on cytokine production
after sepsis
Inflammatory cytokines, including VEGF and HMGB1, have
been implicated as markers and/or pathogenic mediators that
contribute to the severity of sepsis.27,32,36–38 We determined
the dynamic changes of these cytokines during post-
CKD–sepsis. In addition, bilateral nephrectomy plus CLP
was compared with 5/6 Nx-CLP to determine the renal-
specific contribution of these cytokine level changes in the
CKD–sepsis model. Serum HMGB1 increased late after CLP
alone or after bilateral Nx-CLP (Figure 5a). In contrast, in
5/6 Nx mice, HMGB1 was elevated at baseline and increased
early after CLP (Figure 5a). Other cytokines (VEGF, TNF-a,
IL-6, IL-10) were less affected by 5/6 Nx alone (Figure 4c–e),
or 5/6 Nx-CLP compared with CLP alone (ranging from 1.4-
to 2.4-fold), but 5/6 Nx-CLP had larger increases relative to
5/6 Nx alone (3- to 28-fold), comparable to increases
observed with bilateral Nx-CLP (Figure 5b–e). The cytokines
were often higher in bilateral Nx because of increased
cytokine production and/or less renal elimination, as
described by others.39,40 To determine whether kidney
function was important for cytokine elimination, bilateral
Nx or 5/6 Nx was performed; further, exogenous cytokines
were intravenously injected and measured frequently to
calculate cytokine clearance and half-life values. The half-life
of HMGB1 increased by 60% and the half-life of TNF-a, IL-6,
and IL-10 increased by two- to three-fold in 5/6 Nx
compared with normal mice. The half-life for HMGB1,
TNF-a, IL-6, and IL-10 further increased by 31–67% once all
renal function was removed with bilateral Nx (Figure 6). The
pharmacokinetics of VEGF in bilateral Nx could not be
calculated because endogenous VEGF increased as early as
30 min after bilateral Nx (Supplementary Figure S2 online).
A rapid accumulation of VEGF after bilateral Nx is consistent
with the kidney being a dominant organ of VEGF elimina-
tion. Cytokine accumulation in sepsis with preexisting
impaired kidney function was a result, in part, of impaired
renal cytokine elimination, which can contribute to the
higher sepsis severity after 5/6 Nx.
Neutralizing HMGB1, but not VEGF, attenuated sepsis
severity in mice with preexisting CKD (5/6 Nx)
To compare the early VEGF or late HMGB1 contributions to
the severity of sepsis after 5/6 Nx, we used neutralizing
therapies in normal and 5/6 Nx CD-1 mice. Soluble fms-like
tyrosine kinase 1 (sFLT-1) is an endogenous, circulating VEGF
receptor splice variant that can serve as a VEGF antagonist.41
We attempted to counteract the decreased clearance of VEGF
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by neutralizing it with sFLT-1, which was administered
immediately after CLP, then at 3, 6, and 9 h, which attenuated
sepsis severity in normal mice as described previously;23,32,37
however, this was not effective after 5/6 Nx-CLP (Figure 7),
similar to our previous report using a folate kidney fibrosis
model combined with CLP.23 In contrast, a single dose of
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Figure 1 |Widespread exacerbation of sepsis outcomes by chronic kidney disease (CKD). CKD was induced by 5/6 nephrectomy (Nx) in
CD-1 mice, and cecal ligation and puncture (CLP) surgery was performed 4 weeks later. Organ injury was measured at 18 h after sham
(white bar) or CLP (black bar) surgery. Renal function was determined by serum creatinine (Scr) (a) and blood urea nitrogen (BUN) (b), liver
function was determined by alanine transaminase (ALT) (c) and aspartate transaminase (AST) (d), inflammation was determined by serum
cytokine levels (tumor necrosis factor (TNF)-a, interleukin (IL)-6, IL-10) (e–g), renal injury was determined by semiquantitative measurement
of renal vacuolized tubules (h), and splenic apoptosis (i) was measured by activated caspase 3-positive cells per high-power field (HPF)
(n¼ 6–7). *Po0.05 vs. control sham; #Po0.05 vs. control CLP; þPo0.05 vs. 5/6 Nx sham.
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anti-HMGB1 neutralizing antiserum at 6 h after CLP attenu-
ated sepsis severity in 5/6 Nx mice but not in normal mice, as
measured by kidney injury (Scr, BUN), liver injury (ALT, AST),
and inflammatory cytokines (TNF-a, IL-6, IL-10), but not
splenic apoptosis (Figure 8). Furthermore, a single dose of anti-
HMGB1 also improved systemic hemodynamics and delayed
sepsis mortality in preexisting 5/6 Nx with CLP (Figure 9).
Acute splenectomy reduces circulating HMGB1 and the
effectiveness of HMGB1-neutralizing antiserum
Spleen apoptosis can be an important source of serum
HMGB1 both in vitro and in vivo following sepsis.27,36 Because
5/6 Nx accentuates CLP-induced increases in HMGB1, and
anti-HMGB1 therapy was more effective in 5/6 Nx-CLP than
CLP alone, we used splenectomy to determine the contribu-
tion of the spleen to the heightened intensity of disease in the
CKD–sepsis state. Four weeks after 5/6 Nx a splenectomy was
performed, and the levels of HMGB1 decreased by 78% 1 day
later, but the HMGB1 levels returned to control levels within 5
days (Figure 10a). When we performed 5/6 Nx, followed by
acute splenectomy after 4 weeks, and then CLP 3 days later, the
CKD–sepsis-induced increase in HMGB1 was almost com-
pletely diminished (Figure 10b). Further, all other CKD–sepsis-
induced parameters, except AST, were significantly reduced by
acute splenectomy (Supplementary Figure S3 online). After
acute splenectomy, anti-HMGB1 therapy was ineffective at
reducing CKD–sepsis-induced Scr, ALT, and TNF-a (Figure
10c–e), as well as BUN, AST, IL-6, and IL-10 (Supplementary
Figure S4 online).
DISCUSSION
We recently developed a two-stage model of sepsis with
preexisting folate-induced kidney injury and showed that this
comorbidity affected the severity of sepsis.23 Unfortunately,
the transient course of kidney injury after folate does not
match the progressive worsening of human CKD. In the
present study, we used a remnant kidney model that more
closely mimics CKD with respect to progressive hyperten-
sion, glomerulosclerosis, and albuminuria.25 Not only were
we able to confirm our previous findings in a bona fide CKD
model, but we also explored mechanistic pathways that
accelerate the sepsis–AKI phase.
As expected, we found that CKD increased the severity of
all sepsis outcomes that we tested, including splenic
apoptosis. Surprisingly, we found that 5/6 Nx CKD itself
increased splenic apoptosis, in contrast to the folate model,
which did not;23 correspondingly, HMGB1 levels did not
increase in the folate model (data not shown). We
demonstrated that elevated serum HMGB1 was associated
with more severe sepsis. By neutralizing HMGB1 but not
VEGF, sepsis severity could be reduced in mice with CKD,
but not in normal mice. Further, by removing the spleen, we
could transiently decrease HMGB1 levels, reduce the severity
of CKD-sepsis, and eliminate the benefit of anti-HMGB1
therapy.
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Figure 2 |Chronic kidney disease (CKD) increases sepsis-
induced renal tubular vacuolization. Representative images of
periodic acid-Schiff-stained renal cortex in normal CD-1 mice
(a, b), or CD-1 mice 4 weeks after 5/6 nephrectomy (Nx) (c, d) in
sham (a, c) and cecal ligation and puncture (CLP) (b, d).
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Figure 3 |Chronic kidney disease (CKD) enhances sepsis-
induced splenic apoptosis. CD-1 mice were untreated (normal,
a, b) or subjected to 5/6 nephrectomy (Nx) (c, d) 4 weeks before
sham (a, c) or cecal ligation and puncture (CLP) surgery (b, d).
Representative images of spleen stained for activated caspase
3 are shown (a–d); bars¼ 200 mm. Number of activated caspase
3-positive cells per high-power field (HPF) in spleen (e) of
composite control at 16 weeks (wk, n¼ 9); C57BL/6 5/6 Nx at
16 wks (n¼ 4); 129S3 5/6 Nx at 4, 8, and 12 wks (n¼ 4/group);
and CD-1 5/6 Nx at 2 and 4 wks (n¼ 4/group).
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Preexisting CKD predisposes mice to more severe sepsis
We found that the severity of sepsis in relation to kidney,
liver, and spleen injury, or to inflammatory cytokines
(data not shown), corresponded to the strain-dependent
susceptibility of CKD after 5/6Nx in C57BL/6, 129S3, or CD-
1 mice.25 Thus, underlying chronic kidney injury predisposed
mice to more severe sepsis (either with folic acid, as
previously reported,23 or 5/6 Nx in this study), consistent
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with previous studies of host defense defects in CKD, where a
variety of immune cell functions are impaired by yet
undefined factors that presumably include circulating uremic
toxins.9 Because serum inflammatory cytokines, VEGF23,32,37
and HMGB1,27,36 are all increased following sepsis in healthy
mice, we first explored the importance of these factors in
CKD alone, sepsis alone, and the amplification caused by the
sequential combination of preexisting CKD and sepsis.
Inflammatory cytokines. Human and animal studies have
indicated that CKD includes an inflammatory state, with
corresponding increases in inflammatory cytokines (TNF-a,
IL-6, IL-10), which may enhance protein catabolism,
malnutrition, and atherosclerosis.18–20,42 These cytokines are
also elevated in sepsis patients and animal models of
sepsis.2,43,44 We found relatively mild accumulation of these
cytokines in serum, approximately twofold above baseline,
even at late stages of CKD following 5/6 Nx. This was
reflected in a twofold increase in TNF-a, IL-6, and IL-10 after
CKDþ sepsis vs. sepsis alone. Increases in these cytokines
during CKD-sepsis can be attributed, in part, to reduced
renal excretion; 70–80% of the cytokine elimination was via a
renal route. However, strain-dependent severity of CKD25 or
CKDþ sepsis did not change the levels of these cytokines
(data not shown). Thus, a model in which impaired renal
function amplifies inflammation by passively increasing
prototypical pro (TNF-a, IL-6)- and anti-inflammatory
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Figure 7 | Soluble fms-like tyrosine kinase 1 (sFLT-1) attenuated sepsis severity in normal cecal ligation and puncture (CLP) but not
in 5/6 nephrectomy (Nx)-CLP mice. CD-1 mice 4 weeks after 5/6 Nx or normal controls were subjected to sham surgery (white bars) or CLP,
then injected at 0, 3, 6, and 9 h after CLP with normal saline solution (NSS, black bars) or sFLT-1 (33.3mg/kg intravenous, gray bars). The
following were measured 18 h post CLP: renal injury (serum creatinine (Scr), blood urea nitrogen (BUN)) (a, b), liver injury (alanine
transaminase (ALT), aspartate transaminase (AST)) (c, d), inflammatory cytokines (tumor necrosis factor (TNF)-a, interleukin (IL)-6, IL-10) (e–g),
and splenic apoptosis (h), n¼ 4–6/ group. By analysis of variance, there was no significant interaction between chronic kidney disease–sepsis
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(IL-10) cytokine accumulation could only partially account
for the enhanced severity of CKD–sepsis in our experimental
model. It is likely that mild inflammation during CKD can
also interact with the acute inflammation during sepsis to
drive cytokine production. The contribution of these
cytokines to sepsis and CKD–sepsis may not be straightfor-
ward, as treatment with TNF-a can decrease sepsis severity.45
The higher inflammatory cytokine levels that have been
reported in CKD patients may not be central to the
pathogenesis of CKD, but might explain the susceptibility
to infections in CKD.46,47
VEGF. VEGF is increased in CKD both in animals and
humans.23,34 High levels of VEGF can cause vascular
endothelial leakage and have been associated with a higher
severity of human sepsis.30,31 VEGF increased very early after
5/6 Nx surgery and continued to increase in parallel to CKD
progression. Some of this early increase might promote
healing of the surgical wound.48,49 Most exogenously
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administered VEGF was cleared via the kidney, suggesting
that the VEGF increase after CKD was primarily derived by
decreased renal elimination rather than by increased
production. In contrast to prototypical pro- and anti-
inflammatory cytokines, both VEGF and HMGB1 differed
among strains during the progression of CKD (not shown),
and the circulating levels of both mediators corresponded to
the severity of CKD. VEGF increased to very high levels after
sepsis, with or without CKD, as described previously.23,30–32,34,37
We found that exogenously administered sFLT-1, an
endogenous neutralizing, soluble VEGF receptor, did not
attenuate sepsis severity after CKD by 5/6 Nx, nor after
folate-induced fibrotic injury,23 despite the effectiveness of
this treatment in mouse CLP sepsis without preexisting
kidney injury.32,37 Although VEGF participates in both CKD
progression and uncomplicated sepsis–AKI, it does not
synergistically amplify the severity of sepsis after CKD.
HMGB1. The proinflammatory cytokine HMGB1 is
passively released from dying cells that are either undergoing
apoptosis or necrosis,50 and it induces the release of other
cytokines from macrophages and other cell types.51–54
HMGB1 can induce additional release of HMGB1 in
macrophage-like RAW 264.7 cells;27 thus, HMGB1 can
amplify inflammation by positive feedback. In sepsis,
HMGB1 has been proposed as a late-appearing proinflam-
matory cytokine, and HMGB1 neutralizing therapy improved
mortality in normal mice,27,28,51,54,55 even when it was started
24 h after surgery.29 We found that serum HMGB1 increased
in the late phase of CKD and was especially elevated at the
peak of the kidney injury and albuminuria, similar to
observations in a few patients with CKD.26 This time course
suggests that HMGB1 alone does not drive CKD progression,
as HMGB1 levels have probably not reached a critical mass
for positive feedback, but rather accumulate as renal function
deteriorates. Indeed, about half of HMGB1 clearance was
through a renal route. HMGB1 was elevated following sepsis,
but the timing depended on how much renal function
remained before sepsis. HMGB1 was a late-appearing
cytokine (increased at 12 h), as previously demonstrated,28,29
whereas, in sepsis following CKD, HMGB1 was an early-
appearing cytokine (6 h) (Figure 5a). From our data, we
propose the following framework: because HMGB1 levels are
higher during the progression of CKD, and the capacity for
renal clearance of HMGB1 is reduced, the small increases in
HMGB1 during the early phase of sepsis can trigger an
autocrine or positive-feedback loop where HMGB1 is high
enough to induce more HMGB1 release.28,29,55 This view is
supported by a temporal shift in the HMGB1 appearance
from late in sepsis alone to early after CKD–sepsis. On the
other hand, an earlier increase in HMGB1 could be an
indicator of more severe injury as recently mentioned in
moribund trauma patients.56 We found that a single dose of
anti-HMGB1 neutralizing antibody started at 6 h after CLP—
when HMGB1 increased—attenuated sepsis severity and
improved survival in 5/6 Nx-CLP but not in normal CLP
mice. Because neutralizing HMGB1, but not VEGF (by sFLT-
1), was effective, the attenuation of proinflammatory
response might be more beneficial than decreasing vascular
leakage in CKD–sepsis. Alternatively, HMGB1 might drive
VEGF, high levels of VEGF could induce a beneficial
adaptation in endothelial cells, and/or sFLT-1 could have
additional toxic effects, whereas high levels of HMGB1 may
have only harmful effects, including positive feedback. As the
same dose of anti-HMGB1 showed effectiveness only in CLP
with CKD but not CLP alone, HMGB1 might only induce
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Figure 9 |Anti-High Mobility Group Box Protein-1 (HMGB1)
improved sepsis-induced hypotension, bradycardia, and
survival after 5/6 nephrectomy (Nx) and sepsis. Telemetric
recording of conscious mean arterial pressure (MAP) (a) and heart
rate (HR) (b) of normal (red, pink) or 5/6 Nx mice (blue, black)
subjected to cecal ligation and puncture (CLP), and after 6 h
injected with rabbit IgG control (red, blue) or anti-HMGB1 (pink,
black; n¼ 4/group). By repeated-measures analysis of variance
Po0.0001 for either MAP or HR; post hoc (Tukey) comparisons 5/6
Nx-CLPþ IgG control vs. 5/6 Nx-CLPþ anti-HMGB1 was significant
20–38 h post CLP (MAP) and 15–38 h, except 30, 35, and 36 h (HR).
Survival curve (c) of 5/6 Nx mice subjected to CLP, then treatment
6 h later with rabbit IgG control (gray) or anti-HMGB1 (black;
n¼ 7/group). #Po0.05 anti-HMGB1 vs. rabbit IgG control
(Kaplan–Meier analysis).
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tissue damage once it is above a critical threshold. However,
coinduced factors often complicate any simple interpretation.
The higher mean arterial pressure (MAP) in CKD from 5/6
Nx did not help to maintain blood pressure after sepsis. The
MAP started to drop as early as 3 h in both normal and 5/6
Nx mice. Anti-HMGB1 treatment appeared to maintain
cardiovascular function in the ‘late’ sepsis phase (after 18 h),
as reported previously.57–59 However, some of the mice with
improved MAP died after 40–48 h, and additional doses of
anti-HMGB1 might be needed to maximize efficacy.29 Thus,
HMGB1 seems to be more central to the amplification seen
in CKD–sepsis. Anti-HMGB1 treatment, which showed
therapeutic benefit in previous studies on sepsis from healthy
mice,27,29,36 might have a greater impact on sepsis with
underlying CKD. We summarize how our findings fit into
our current understanding in Figure 11. Considering the
increasing prevalence of CKD patients with a higher rate of
sepsis9 and longer lengths of hospital stay,10 HMGB1 may be
a promising target as part of a combination preemption and/
or treatment strategy.
Role of spleen apoptosis in HMGB1 accumulation in
CKD–sepsis
We then turned to cellular immune defects, as both CKD and
sepsis are associated with immunomodulatory and immune
depression defects9,60 including uremia-induced immune cell
90
*
*
*
75
60
45
30
15
0
350
280
210
140
70
0
1.5
600
500
400
300
200
100
0
TN
F-
α
 
(pg
/m
l)
1.0
0.5
0.0
Sham (d3) IgG Anti-HMGB1
Sham (d3) IgG Anti-HMGB1
CLP (d3)
Sc
r (
mg
/dl
)
Sham (d3) CLP (d3) Splx (d0)+CLP (d3)
H
M
G
B1
 (n
g/m
l)
4wk after 5/6 Nx 4wk after 5/6 Nx, Splx at d0
4wk after 5/6 Nx, Splx at d0
0–1 1 3
5/6 Nx
5/6 Nx+Splx (d0)
5 7
Time after Splx (days)
H
M
G
B1
 (n
g/m
l)
CLP (d3)
600
500
400
300
200
100
0
AL
T 
(U
/L)
CLP (d3)
4wk after 5/6 Nx, Splx at d0
Sham (d3) IgG Anti-HMGB1
Figure 10 | Splenectomy transiently decreases High Mobility Group Box Protein-1 (HMGB1) and renders anti-HMGB1 ineffective in
treating chronic kidney disease (CKD)–sepsis. CD-1 mice were subjected to 5/6 nephrectomy (Nx), and after 4 weeks (wks) splenectomy
was performed at day 0. Serum HMGB1 (a) was measured in 5/6 Nx controls (black squares) or 5/6 Nx splenectomy (white squares).
Loss of CKD–sepsis-stimulated serum HMGB1 (b): 4 wks after 5/6 Nx, mice were subjected to splenectomy (gray bar), and after 3 days sham
surgery (white bar) or cecal ligation and puncture (CLP, black bar, gray bar) was performed, and serum HMGB1 was measured after 18 h.
Outcomes of CKD–sepsis (see also Supplementary Figure S4 online): 4 wks after 5/6 Nx, mice were subjected to splenectomy (day 0, d0),
and after 3 days sham surgery (white bars) or CLP (black bars, gray bars) was performed, followed by administration of control IgG
(black bars) or anti-HMGB1 (gray bars) 6 h later, and then measurement of serum creatinine (Scr) (c), alanine transaminase (ALT) (d), or tumor
necrosis factor (TNF)-a (e) at 18 h. d3, day 3; Splx, splenectomy.
CKD
(chronic)
a b cSepsis AKI
(acute)
Cytokines
VEGF
spleen apoptosis/HMGB1
Cytokines
VEGF
spleen apoptosis/HMGB1
Cytokines
VEGF
spleen apoptosis/HMGB1
Cytokines
VEGF
spleen apoptosis/HMGB1
Severity
Time
CKD+sepsis AKI
(acute-on-chronic)
Figure 11 |Proposed framework for acute-on-CKD (chronic
kidney disease). CKD progresses slowly (a), and after a septic
insult the trajectory accelerates (c) relative to uncomplicated
sepsis–acute kidney injury (AKI) (b). This acceleration may be
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apoptosis in CKD.11,61–65 Because HMGB1 is released from
apoptotic cells,29 we explored the role of the spleen, the
largest lymphoid organ66–68 and a major site of apoptosis
following sepsis.36 We surprisingly found spleen apoptosis in
CKD (before CLP surgery) that started as early as 4 and 8
weeks after 5/6 Nx in CD-1 and 129S3 mice, respectively.
Although CKD and uremia can induce immune cell
apoptosis, we could not find any previous animal or human
studies of spontaneous cell apoptosis in lymphoid organs that
could support our findings. Splenic apoptosis appears to be
upstream of HMGB1, as recombinant HMGB1 administra-
tion (6 mg/kg) did not induce splenic apoptosis even after
bilateral Nx (data not shown), HMGB1 neutralizing antibody
treatment of CKD–sepsis did not decrease splenic apoptosis,
and HMGB1 levels decreased transiently by splenectomy.
Because splenectomy eliminated the effectiveness of anti-
HMGB1 treatment, our data are consistent with spleen
apoptosis being an important source of HMGB1 during
CKD–sepsis; however, because splenectomy does not distin-
guish between apoptotic and non-apoptotic cells, we cannot
rule out the impact of other functions of the spleen on
CKD–sepsis.
The role of spleen apoptosis in the pathogenesis and
progression of CKD remains an open question because
splenectomy only transiently reduced HMGB1 levels. We
speculate that the CKD- and/or sepsis-induced trigger(s) of
lymphocyte apoptosis remain after splenectomy and induce
apoptosis in other lymphoid cells in lymph nodes, thymus,
liver, or the circulation, with subsequent increases in
HMGB1.
Conclusion
Successfully translating treatments from preclinical animal
models to human patients have been exceedingly difficult in
sepsis. 2–6 Some of this difficulty may arise because the animal
models do not faithfully reproduce enough features of
human sepsis; alternatively, candidate drugs are typically
tested in young healthy animals, whereas a majority of sepsis
occurs in the setting of preexisting medical conditions.9 We
modified the standard CLP model to incorporate a common
preexisting condition, progressive CKD, thereby creating a
more clinically relevant model that more closely resembles
the complexity of human sepsis. We found that preexisting,
progressive CKD amplified sepsis, and that HMGB1 was a
major amplification factor, which was not cleared by the
injured kidney. In addition, we found that 5/6 Nx CKD
increased spleen apoptosis, which appeared to be an
important source of elevated serum HMGB1 level in CKD.
A high baseline level of HMGB1 in CKD might trigger
additional HMGB1 release after sepsis, resulting in a positive-
feedback loop. Interception with anti-HMGB1 reduced sepsis
after CKD but not in normal animals or CKD animals shortly
after splenectomy. Thus, the two-stage CKD–sepsis model has
markedly increased mortality and divergent mechanisms/
therapeutic targets than a sepsis model in young mice.
Models that more closely replicate the underlying comorbid-
ity might be more suitable for testing biomarkers and
therapeutic agents for use in human sepsis.
The interplay between CKD and sepsis is inherently
complex. By comparing both CKD and sepsis components
with CKD–sepsis, we can begin to isolate which progression
factors for CKD and sepsis function in concert, which factors
function independently, and which factors may even counter-
act. For example, routine examination of baseline values of
typical sepsis outcomes post-CKD/pre-sepsis led to our
discovery of splenic apoptosis as a potentially important
mediator of CKD progression. This unconventional line of
thinking was made possible by dissecting the complex clinical
problem of CKD–sepsis into two distinct and disparate
components, and then systematically examining the models
for each component alone or in combination.
MATERIALS AND METHODS
Animals and animal models
Animal care and experiments were performed according to the
National Institutes of Health (NIH) criteria for the care and use of
laboratory animals in research. Male 6- to 8-week-old CD-1
(Charles River Laboratories, Wilmington, MA), 129S3, or C57BL/6
(NCI-DCT, Frederick, MD) mice had free access to water and chow.
Morbidly ill mice were euthanized as per protocol. All surgical
procedures were performed under isoflurane anesthesia.
Nephrectomy
The 5/6 Nx was performed in two stages: upper and lower pole
kidney removal (2/6 Nx), followed by right nephrectomy (3/6 Nx) 1
week later as described previously.25 Mice were used only if adequate
kidney mass was removed (a ratio of removed left kidney fragments
to right kidney between 0.55 and 0.72). In partial nephrectomy
controls (2/6 Nx), the same first-stage procedure was followed 1 week
later by right-flank incision and identification of both poles of the
right kidney. Similarly, sham normal mice had two flank incisions, 1
week apart, where both poles of left and right kidney were identified.
Bilateral nephrectomy was performed via bilateral flank approach as
described previously.69 The renal capsule was peeled away before
partial or total nephrectomy in order to avoid adrenal gland injury.
Polymicrobial cecal ligation and puncture
CLP was performed as described previously.70 In short, we ligated
the cecum at 12 mm in length and punctured twice with a 21-gauge
needle, then gently squeezed to express a small amount of fecal
material, and returned to the central abdominal cavity. In sham-
operated animals, the cecum was isolated, but neither ligated nor
punctured. Prewarmed normal saline (30 ml/kg) was immediately
given intraperitoneally after surgery and antibiotic was given
subcutaneously (imipenem/cilastatin; 14 mg/kg in 1 ml of normal
saline) 6 h later. At 18 hours after surgery, blood was collected by
cardiac puncture for measurement of serum markers of organ injury
and cytokine response. Kidneys, liver, and spleen were fixed in 10%
neutral-buffered formalin for histology.
Splenectomy
Splenectomy was performed as described previously70 via left flank 3
days before or immediately before CLP in normal or 5/6 Nx mice
and immediately after bilateral nephrectomy (via left flank after left
kidney removal).
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Drug administration
Recombinant human soluble FLT-1 domain D1-3 (1 mg per 30 g
mouse; sFLT-1: Cell Sciences, Canton, MA; or an equal volume of
NSS for sham treatment) was injected intravenously every 3 h (four
doses), starting immediately after CLP.23 A single dose of anti-
HMGB1 neutralizing antibody, which was generously supplied by
Dr Kevin J. Tracey (Feinstein Institute for Biomedical Research,
Long Island, NY),29 or purified rabbit IgG (Sigma-Aldrich, St Louis,
MO), was injected intraperitoneally (3.6 mg/kg)29 6 h after CLP in
CD-1 mice either untreated (‘normal’) or 4 weeks after 5/6 Nx.
Blood chemistries and cytokine measurements
At week 0 (immediately before second-stage operation: 1 week after
both pole resection), 1, 2, 4, 8, and 12 h after CLP surgery, 60 ml of
capillary tube blood was collected by retro-orbital approach under
isoflurane anesthesia, and then centrifuged at 1000 g for 8 min
to remove cells. VEGF, TNF-a, IL-6, IL-10 (R&D Systems, Minneapolis,
MN), and HMGB1 (Shino-Test Corporation, Kanagawa, Japan)71
were measured by ELISA. BUN, AST, and ALT were measured by
using an autoanalyzer (Hitachi 917, Boehringer Mannheim,
Indianapolis, IN). Scr was measured by high-performance liquid
chromatography.72
Histology
The 10% formalin-fixed, paraffin-embedded kidney sections were
stained with periodic acid-Schiff reagent (Sigma-Aldrich). Renal
tubular damage caused by CLP-induced sepsis was assessed by
counting vacuolized tubules per 200 total tubules per field using 10
randomly selected fields from each animal at  400 magnification.
Immunohistochemical staining of 4 mm paraffin sections was
performed as previously described with antiactive caspase 3
antibody (Cell Signaling Technology, Beverly, MA), a marker of
apoptosis, was examined in five randomly chosen  200 fields, and
expressed as positive cells per high-power field.23,70
Pharmacokinetics of cytokines
A single dose of recombinant cytokine was injected intravenously in
normal CD-1 mice immediately after sham surgery, and in 5/6 Nx
CD-1 mice at 4 weeks and immediately after bilateral Nx: mouse
TNF-a, IL-6, IL-10, VEGF (eBioscience, San Diego, CA) and
recombinant human HMGB1 (R&D Systems, Minneapolis, MN) at
doses of 0.03mg, 3mg, 0.3mg, 0.03mg, and 6 mg/kg, respectively. Each
dose of cytokine was validated to have no effect on endogenous
cytokine production (data not shown). A volume of 60ml of capillary
blood collected via retro-orbital sinus at least 1 day before injection as
a baseline and at 5 min, 0.5, 1, 3, 5, 8, or 24 h after injection was used
to measure an individual cytokine. Area under the concentration time
curve from 0–24 h (AUC024 h) was calculated by trapezoidal rule.
73
Elevated levels of HMGB1 and VEGF after 5/6 Nx were assumed to be
in steady state, and pharmacokinetics parameters were calculated after
subtraction of the baseline level. Previously described equations74,75
were used for pharmacokinetic parameters: (1) Ke¼maximal
concentration/ AUC024 h; (2) half-life (t1/2)¼ 0.693/Ke; (3) volume
of distribution (Vd)¼ known injected dose/maximal concentration;
(4) Clearance (CL)¼ 0.693*Vd/t1/2. The cytokine level 5 min after
injection was used as maximal concentration.
Measurement of blood pressure
MAP was measured by radiotelemetry as described previously.23,76
A telemeter transmitter (model TA11PA-C10, Data Sciences
International, St Paul, MN) was implanted 1 week before
subsequent data acquisition.
Survival study
Survival after CLP surgery was determined by conventional methods
and confirmed by telemetric recordings of MAP and heart rate.
Imipenem/cilastatin (14 mg/kg) and fluid resuscitation (1 ml of
normal saline) were started 6 h after CLP by subcutaneous injection
and then repeated with 7 mg/kg imipenem/cilastatin in 1 ml of
normal saline every 12 h for 4 days. Morbidly ill animals were killed.
Statistical analysis
Differences between the groups were examined for statistical
significance by Student’s t-test or analysis of variance with
appropriate multiple comparison corrections (SigmaStat 3.1, Systat
Software, Point Richmond, CA); longitudinal measurements were
analyzed by repeated-measures analysis of variance to test time-
dependent interactions (SAS, Cary, NC). When the statistical model
was significant, further post hoc analyses were performed by Tukey’s
method for multiple comparisons. A P-valueo0.05 was accepted as
statistically significant.
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